Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale

Parkinsonism and Related Disorders

Volumn 25, Issue , 2016, Pages 39-44

  van der Heeden, Jorine F ^a   Marinus, Johan ^a   Martinez Martin, Pablo ^b   van Hilten, Jacobus J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Non dopaminergic symptoms; Parkinson's disease; Progression; Severity

Indexed keywords

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BODY EQUILIBRIUM; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; DAYTIME SOMNOLENCE; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; FEMALE; GAIT DISORDER; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RELIABILITY; SCORING SYSTEM; SENS-PD SCALE; VALIDITY; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84959087110     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.02.016     Document Type: Article

References (30)

1. [1] Jellinger, K.A., Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 27 (2012), 8–30.
2. [2] van der Heeden, J.F., Marinus, J., Martinez-Martin, P., van Hilten, J.J., Importance of nondopaminergic features in evaluating disease severity of Parkinson disease. Neurology 82 (2014), 412–418.
3. [3] Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., Movement Disorder Society UPDRS revision task force, movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23 (2008), 2129–2170.
4. [4] Chaudhuri, K.R., Martinez-Martin, P., Brown, R.G., Sethi, K., Stocchi, F., Odin, P., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov. Disord. 22 (2007), 1901–1911.
5. [5] van Rooden, S.M., Visser, M., Verbaan, D., Marinus, J., van Hilten, J.J., Patterns of motor and non-motor features in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80 (2009), 846–850.
6. [6] Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51 (1988), 745–752.
7. [7] ELEP group, A longitudinal study of patients with Parkinson's disease (ELEP): aims and methodology. Rev. Neurol. 42 (2006), 360–365.
8. [8] Verbaan, D., Marinus, J., Visser, M., van Rooden, S.M., Stiggelbout, A.M., van Hilten, J.J., Patient-reported autonomic symptoms in Parkinson disease. Neurology 69 (2007), 333–341.
9. [9] Marinus, J., Visser, M., Stiggelbout, A.M., Rabey, J.M., Martinez-Martin, P., Bonuccelli, U., Kraus, P.H., van Hilten, J.J., A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J. Neurol. Neurosurg. Psychiatry 75 (2004), 388–395.
10. [10] Visser, M., Verbaan, D., van Rooden, S.M., Stiggelbout, A.M., Marinus, J., van Hilten, J.J., Asessment of psychiatric complications in Parkinson's disease: the SCOPA-PC. Mov. Disord. 22 (2007), 2221–2228.
11. [11] Marinus, J., Visser, M., van Hilten, J.J., Lammers, G.J., Stiggelbout, A.M., Assessment of sleep and sleepiness in Parkinson disease. Sleep 26 (2003), 1049–1054.
12. [12] Visser, M., Marinus, J., Stiggelbout, A.M., van Hilten, J.J., Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov. Disord. 19 (2004), 1306–1312.
13. [13] Marinus, J., Visser, M., Verwey, N.A., Verhey, F.R., Middelkoop, H.A., Stiggelbout, A.M., van Hilten, J.J., Assessment of cognition in Parkinson's disease. Neurology 61 (2003), 1222–1228.
14. [14] Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (1983), 361–370.
15. [15] Hoehn, M.M., Yahr, M.D., Parkinsonism: onset, progression and mortality. Neurology 17 (1967), 427–442.
16. [16] Esselink, R.A., de Bie, R.M., de Haan, R.J., Lenders, M.W., Nijssen, P.C., Staal, M.J., Smeding, H.M., Schuurman, P.R., Bosch, D.A., Speelman, J.D., Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 62 (2004), 201–207.
17. [17] Aaronson, N., Alonso, J., Burnam, A., Lohr, K.N., Patrick, D.L., Perrin, E., Stein, R.E., Assessing health status and quality-of-life instruments: attributes and review criteria. Qual. Life Res. 11 (2002), 193–205.
18. [18] Field, A., Discovering Statistics Using SPSS. third ed., 2009, SAGE Publication Ltd, London.
19. [19] Clark, L.A., Watson, D., Constructing validity: basic issues in objective scale development. Psychol. Assess. 7 (1995), 309–319.
20. [20] Nunnally, J.C., Bernstein, I.H., Psychometric Theory. third ed., 1994, McGRAW-HILL, INC, New York.
21. [21] McHorney, C.A., Tarlov, A.R., Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual. Life Res. 4 (1995), 293–307.
22. [22] Chaudhuri, K.R., Healy, D.G., Schapira, A.H., Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5 (2006), 235–245.
23. [23] Marinus, J., Leentjens, A.F., Visser, M., Stiggelbout, A.M., van Hilten, J.J., Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin. Neuropharmacol. 25 (2002), 318–324.
24. [24] Verbaan, D., van Rooden, S.M., Benit, C.P., van Zwet, E.W., Marinus, J., van Hilten, J.J., SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson's disease. Park. Relat. Disord. 17 (2011), 632–634.
25. [25] Jost, W.H., Gastrointestinal dysfunction in Parkinson's Disease. J. Neurol. Sci. 289 (2010), 69–73.
26. [26] Muller, B., Assmus, J., Larsen, J.P., Haugarvoll, K., Skeie, G.O., Tysnes, O.B., Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurol. Scand. 127 (2013), 290–294.
27. [27] Chaudhuri, K.R., Schapira, A.H., Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8 (2009), 464–474.
28. [28] Connolly, B.S., Lang, A.E., Pharmacological treatment of Parkinson disease: a review. JAMA 311 (2014), 1670–1683.
29. [29] Knie, B., Mitra, M.T., Logishetty, K., Chaudhuri, K.R., Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 25 (2011), 203–212.
30. [30] Curtze, C., Nutt, J.G., Carlson-Kuhta, P., Mancini, M., Horak, F.B., Levodopa is a double-edged sword for balance and gait in people with Parkinson's disease. Mov. Disord. 30 (2015), 1361–1370.